Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Two posters of relevance to SNG at the ERS today, one on UNIVERSAL and the other by Dr Monk summarising data from SNG001 trials. Both have been flagged here since the ERS programme was announced a coupl3 of months ago.
I’ve just seen this BBC report:
https://www.bbc.co.uk/news/health-66750359
Seems that 7 out of 35 patients with Covid-19 required admission to hospital. Most from a nursing home so presumably with a good vaccination history. 20% hospitalisation rate in this demographic.
I would suggest caution in interpreting “future, larger studies”. This is a paper more about the success of a “virtual” study technique than about the material under study. Envisaged future, larger studies may adopt the same distance-based, “virtual” approach, but not necessarily in relation to SNG001.
The medical consensus, unlike that of the world at large currently, is that Covid-19 has joined the ranks of influenza and respiratory syncytial virus, among others, as a permanent challenge to human health.
The good news it that vaccination and exposure-driven immunity have made huge inroads into susceptibility to the virus at a population level. The less good news is that what works for populations as a whole does not necessarily do so for susceptible individuals including the frail, the elderly and the immunocompromised. Mono-clonal antibody based therapies have a part to play but will, forever, be playing catch-up in the battle agains an agile viral master of disguises, able to change its appearance, and therefore, recognisability to antibodies, almost at will. Also on the bad news front, it is proving impossible to squeeze Covid-19 into the “winter flu season” paradigm and its annual vaccine production and administration model. We have seen waves and surges in all seasons.
It’s too early to judge but BA.2.86 is probably not going to turn out t9 be the “big one” in terms of its virulence. But it shows what we are up against and is an indicator of what we are going to face time and again in perpetuity. This is the true context in which we are supporting a small company working to produce a virus and variant agnostic therapeutic effective in this critical battle. The commercial success of SNG001 remains uncertain but none of us should regret our decision to back it. In my opinion it will prove to become an important weapon in the fight against respiratory viral infections, including Covid-19.
Very interesting, The_Paladin. An application for 001 would stand a fair to good chance of success imo but the tactics would need to be worked out carefully: there would be very substantial costs entailed in gearing up to manage the consequences of a successful application - production, distribution, establishment of a register, monitoring, etc. These might be prohibitive for a company the size of SNG. Had the pathway been in place in mid 2020, things might have been different.
MS requires a systemic effect, thus a systemic mode of administration - cheap. SNG001’s USP is maximising effect in the lung with minimal systemic spillover - at substantial cost.
MS requires a systemic effect, thus a systemic mode of administration - cheap. SNG001’s USP is maximising effect in the lung with minimal systemic spillover - at substantial cost.
Courtesy of Reddit, this pre-print review paper opines that IFNs have “colossal potential in the treatment of SARS-CoV-2 infection”
https://www.preprints.org/manuscript/202307.0367/v1
“ATS 2023 Respiratory Innovation Summit
Washington DC Marriott Marquis
901 Massachusetts Ave NW
Washington, DC 20001
Hosted by the American Thoracic Society, the 2023 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways. This meeting historically attracts 275+ global leaders representing all facets of the respiratory industry, including representatives from start-ups, business development, venture capital, government, academia and clinical medicine.
All companies innovating in pulmonary, critical care or sleep are encouraged to apply. All applications will be reviewed; 75 companies will be selected for poster presentation. Of those, 20-25 will be also programmed for oral presentation. The agenda also includes venture capital panels, business development panels and plenty of time for networking.”
Thank you, Titania, for sharing this link that I copy here in an attempt to prevent it disappearing under the welter of domestobabble currently dominating the board. Yet further evidence of the centrality of IFN beta to the severity of COVID in individuals.
https://pubmed.ncbi.nlm.nih.gov/36451263/
So Janssen is “funding” UNIVERSAL, AZ are providing the funding for a key component of the study (specimen testing) and Synairgen are providing access to equipment and research nurses’ time. Interesting collaborative effort. May one assume that all 3 companies have access to the results of the study?
Yes, it is an advert. Synairgen must believe that money spent on this kind of high end promotion is worthwhile. This, together with their staff recruitment and retention performance of late suggests strongly to me that there is something positive afoot down Southampton way.
Ok, it’s not the Holy Grail we have all been waiting for, and of course it was a paid-for event but it’s still good to see promotion of awareness of Synairgen in a very prestigious publication. Of course this pr initiative is a side show to the main event but a necessary one, imo, and one that is being carried out quite well by the company